Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 1998

View Archived Issues

40th PDR Annual General Meeting

New drug delivery technology soon to enter clinical testing

Alliance decisively moves ahead with development of blood substitute

Amgen expands calcimimetic drug development

CIMA completes study of Zomig using OraSolv technology

Melatonin prevents doxorubicin-induced cardiotoxicity in rat model

CollaGenex enters copromotion agreement with SmithKline Beecham

Access signs agreement for amlexanox distribution in four additional markets

Negotiations between Altana and Hyal for licensing Solarase terminated

Lead compound generated in Structural Bioinformatics/BioChem Pharma collaboration

Genome Therapeutics first to sequence strains of Enterobacter and Acinetobacter

Orquest seeks European marketing clearance for Healos

Lundbeck describes novel class for psychiatric and neurological disorders

Orally active thrombin inhibitors prepared at ADIR as anticoagulants

Subtype-selective 5-HT1D agonists developed at MS&D for migraine

Bristol-Myers Squibb discloses novel MTP inhibitors

New U.S. patent covers use of anti-CTGF antibodies to treat fibrotic disorders

Nitromethylthiobenzene derivatives as aldose reductase inhibitors

Xenova and Warner-Lambert extend NatChem drug discovery collaboration

5-HT2A receptor antagonist shows potent antithrombotic activity in rat model

Atridox now being sold in the U.S. through Block Drug

Promising results obtained with efavirenz in the treatment of pediatric HIV infection

Rabeprazole effective for GERD and ulcers: data presented at gastroenterology congress

2-5A-antisense chimer provides potent inhibition of RSV replication

Verapamil recommended for first-line treatment of cluster headache

Clinical results cast further doubt on the role of substance P in migraine

DepoTech withdraws MAA for Savedar for solid tumor indication

Glaxo Wellcome submits NDA for new HIV protease inhibitor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...